Literature DB >> 17086937

Drug evaluation: ranirestat--an aldose reductase inhibitor for the potential treatment of diabetic complications.

Nick Giannoukakis1.   

Abstract

Ranirestat is an orally available aldose reductase inhibitor under development by Dainippon Sumitomo Pharma Co Ltd (formerly Dainippon Pharmaceutical Co Ltd), Kyorin Pharmaceutical Co Ltd and Eisai Co Ltd for the potential treatment of diabetic complications, such as neuropathy, cataracts, retinopathy and nephropathy. Phase III trials were ongoing in February 2006.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17086937

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  4 in total

1.  Recent Progress on the Stereoselective Synthesis of Cyclic Quaternary alpha-Amino Acids.

Authors:  Carlos Cativiela; Mario Ordóñez
Journal:  Tetrahedron Asymmetry       Date:  2009-01-30

2.  Binding Studies of Caffeic and p-Coumaric Acid with α-Amylase: Multispectroscopic and Computational Approaches Deciphering the Effect on Advanced Glycation End Products (AGEs).

Authors:  Mohd Shahnawaz Khan; Majed S Alokail; Amal Majed H Alenad; Nojood Altwaijry; Nouf Omar Alafaleq; Abdulaziz Mohammed Alamri; Mubarak Ali Zawba
Journal:  Molecules       Date:  2022-06-21       Impact factor: 4.927

Review 3.  Phlorotannins: Towards New Pharmacological Interventions for Diabetes Mellitus Type 2.

Authors:  Graciliana Lopes; Paula B Andrade; Patrícia Valentão
Journal:  Molecules       Date:  2016-12-30       Impact factor: 4.411

4.  Aldose reductase, oxidative stress, and diabetic mellitus.

Authors:  Wai Ho Tang; Kathleen A Martin; John Hwa
Journal:  Front Pharmacol       Date:  2012-05-09       Impact factor: 5.810
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.